Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis finds no significant association between diabetic retinopathy and age-related macular degenerationDiabetic retinopathy and age-related macular degeneration show no significant link

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that current evidence shows no significant association between diabetic retinopathy and age-related macular degeneration.

This systematic review and meta-analysis examines the association between diabetic retinopathy and age-related macular degeneration. The authors analyze existing literature to determine if a link exists between these two common eye conditions. The synthesis of available data reveals no significant relationship between diabetic retinopathy and age-related macular degeneration. No specific effect sizes or absolute numbers were reported in the source material.

The authors note that existing evidence is primarily based on unadjusted data. Additionally, the analysis found high between-study heterogeneity among the included studies. These factors limit the ability to draw firm conclusions about the true nature of the association between the two conditions. The lack of adjustment for confounding variables is a significant limitation in the current body of evidence.

The practice relevance of this work emphasizes the need for well-designed prospective cohort studies. Such studies should account for confounding variables and treatment effects to provide clearer insights. Until such data are available, clinicians should interpret the current lack of association with caution. The findings do not establish causality or rule out a relationship that might exist under adjusted analysis.

This systematic review and meta-analysis looked at the connection between diabetic retinopathy and age-related macular degeneration. The researchers combined data from multiple studies to see if one condition was linked to the other. The main result showed no significant relationship between the two eye conditions. No safety concerns or adverse events were reported because the study focused on associations rather than treatments.

However, the existing evidence is primarily based on unadjusted data. This means the studies did not fully account for other factors that might influence the results. There was also high between-study heterogeneity, which suggests the different studies varied too much to draw a single firm conclusion.

Readers should take this with caution. The main reason to be careful is that the data lacks the depth of well-designed prospective cohort studies. Future research needs to account for confounding variables and treatment effects to provide clearer answers. Until then, this analysis highlights the need for better-designed studies rather than changing current medical practices.

What this means for you:
No significant link found between diabetic retinopathy and age-related macular degeneration in current unadjusted data.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
KEY MESSAGES: WHAT IS KNOWN : • Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are leading causes of visual impairment, and both share overlapping pathogenic mechanisms such as oxidative stress and vascular dysfunction. • Previous studies exploring the association between DR and AMD have reported inconsistent findings, with some suggesting DR as a risk factor and others reporting a protective association. WHAT IS NEW: • This is the first systematic review and meta-analysis specifically examining the association between DR and AMD. • Our results demonstrate no significant relationship between DR and AMD, despite high between-study heterogeneity and robust sensitivity analyses. • The findings highlight that existing evidence is primarily based on unadjusted data, emphasizing the need for well-designed prospective cohort studies that account for confounding variables and treatment effects.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.